Atlas Trials

Secondary Hypogonadism

21 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Secondary Hypogonadism

RecordFirmDate
Safety and Efficacy Study of Oral Fispemifene for the Treatment of Sexual Dysfunction in Hypogonadal Men (NCT02443090)NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.)2015-05-01
A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62% (NCT01993212)Repros Therapeutics Inc.2014-01-01
A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62% (NCT01993225)Repros Therapeutics Inc.2014-01-01
Evaluation of Pharmacokinetic and Safety Profile of Androxal in Male Subjects With Impaired Renal Function (NCT01923857)Repros Therapeutics Inc.2013-08-01
Evaluation of the Pharmacokinetics and Safety of Androxal in Male Subjects With Impaired Hepatic Function (NCT01923870)Repros Therapeutics Inc.2013-08-01
An Extension Study of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism (NCT01739582)Repros Therapeutics Inc.2012-11-01
Phase III Study to Evaluate Morning Testosterone Normalization in Overweight Men With Secondary Hypogonadism (NCT01739595)Repros Therapeutics Inc.2012-11-01
Phase III Study to Evaluated Morning Testosterone Normalization in Men With Secondary Hypogonadism (NCT01532414)Repros Therapeutics Inc.2012-08-01
Safety Study of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism (NCT01534208)Repros Therapeutics Inc.2012-05-01
The Effect on Androxal Versus Androgel on Morning Testosterone in Men With Secondary Hypogonadism (Low Testosterone) (NCT01386606)Repros Therapeutics Inc.2011-06-01
Normalization of Morning Testosterone Levels in Men With Secondary Hypogonadism (NCT01270841)Repros Therapeutics Inc.2011-01-01
Study to Evaluate the Efficacy of Androxal in Controlling Blood Glucose in Men With Type-2 Diabetes Mellitus (NCT01191320)Repros Therapeutics Inc.2010-10-01
Pharmacokinetic Study to Determine Time to Steady-state (NCT00911586)Clarus Therapeutics, Inc.2009-07-01
To Evaluate Sperm Parameters in Men With Secondary Hypogonadism Previously Treated With Topical Testosterone (NCT00706719)Repros Therapeutics Inc.2008-06-01
Long-term Safety Study of Intramuscular Injections of 750 mg and 1000 mg Testosterone Undecanoate in Hypogonadal Men (NCT00467870)Endo USA Inc., a Keenova Therapeutics Company2006-03-01
Study to Evaluate the Safety and Efficacy of Androxal Treatment in Men With Secondary Hypogonadism (NCT01067365)Repros Therapeutics Inc.2006-03-01
Study to Evaluate the Safety and Efficacy of Androxalâ„¢ Treatment in Men With Secondary Hypogonadism (NCT00962637)Repros Therapeutics Inc.2006-03-01

Track Secondary Hypogonadism automatically

Every clearance here is in the API, with alerts when new ones post.